YOLFTbeta
30

Guangdong Taienkang Pharmaceutical Co. Ltd

301263 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

18.71CNY-0.36 (-1.89%)

Price History

Full chart

Market Stats

Previous Close19.07
Open19.15
Day Range18.70 – 19.48
52-Week Range17.52 – 29.72
Volume2.62M
Market Cap9.75B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.22%
Beta0.29
50-Day Avg19.89
200-Day Avg22.41

About

Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the form of tablets, pills, injections, and essential oils; medical technology and technology transfer services; and medical devices. It also operates as an agent for pharmaceutical products; and offers medical and sanitary materials, masks, sutures, surgical staplers, vascular clips and clip appliers, etc., as well as non-prescription drugs. The company was formerly known as Shantou Taikang Pharmaceutical Co., Ltd. and changed its name to Guangdong Taienkang Pharmaceutical Co., Ltd. in June 2006. Guangdong Taienkang Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Shantou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Hanjie Zheng
  • Employees1.15K
  • HeadquartersBuilding A, Shantou, China, 515041, China
  • Websitehttps://www.tai-kang.com.cn

Leadership

  • Mr. Hanjie ZhengGM & Chairman · b. 1963
  • Ms. Guixi ZhouAccounting Supervisor & Financial Director · b. 1987
  • Mr. Ting LiDirector, Deputy GM & Secretary of the Board · b. 1983
  • Mr. Tao SunDeputy General Manager · b. 1976
  • Mr. Zhen ZhangDeputy General Manager · b. 1976
  • Ms. Zili LinDeputy General Manager · b. 1976

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue496.39M708.98M653.65M783.48M760.79M721.03M674.90M
Growth (%)-+42.83%-7.80%+19.86%-2.90%-5.23%-6.40%
Cost of Revenue285.32M320.30M326.03M327.39M299.72M312.48M310.07M
Gross Profit211.07M388.69M327.62M456.09M461.06M408.55M364.83M
Gross Margin42.52%54.82%50.12%58.21%60.60%56.66%54.06%
Operating Expense140.63M179.74M182.63M255.47M270.21M293.33M351.70M
Operating Income70.44M208.95M144.99M200.62M190.85M115.22M13.14M
Operating Margin14.19%29.47%22.18%25.61%25.09%15.98%1.95%
EBITDA139.36M257.99M175.23M243.00M233.06M168.62M70.28M
EBITDA Margin28.07%36.39%26.81%31.02%30.63%23.39%10.41%
Net Income54.90M160.83M120.07M174.61M160.20M108.22M28.63M
Net Income Margin11.06%22.68%18.37%22.29%21.06%15.01%4.24%
R&D24.04M31.34M26.46M40.39M62.89M86.42M77.68M
R&D as % of Total Revenue4.84%4.42%4.05%5.16%8.27%11.99%11.51%
Interest Expense25.32M5.14M4.72M2.58M1.70M8.63M12.63M
Interest Expense % of Total Revenue5.10%0.72%0.72%0.33%0.22%1.20%1.87%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets679.56M834.75M941.52M2.04B2.23B2.31B2.42B
Total Liabilities181.16M245.12M231.71M185.63M399.72M494.67M676.07M
Total Equity496.39M589.72M709.96M1.85B1.79B1.77B1.67B
Cash79.95M93.50M137.63M806.79M455.64M541.96M579.72M
Net Debt-32.92M-----

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow75.44M125.53M120.02M148.81M93.53M89.33M-12.88M
Capital Expenditure8.83M93.12M44.65M89.88M200.01M68.55M108.28M
Free Cash Flow66.61M32.41M75.38M58.94M-106.48M20.78M-121.16M
Dividends Paid82.36M68.14M4.27M85.81M166.78M135.12M93.58M
FCF to OCF88.29%25.82%62.80%39.60%-113.85%23.26%940.86%
Dividend Paid to FCF123.65%210.26%5.67%145.60%-156.63%650.23%-77.24%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual0.110.050.100.090.100.110.060.040.090.080.06-0.020.060.01-0.01-0.010.06-0.05
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap9.75B
Enterprise Value10.88B
Trailing P/E0.00
Forward P/E0.00
Price / Sales15.04
Price / Book6.74
EPS-0.01
Book Value3.12
Revenue (TTM)648.09M
Gross Profit (TTM)345.09M
EBITDA22.48M
Profit Margin-0.73%
Operating Margin-39.02%
Return on Equity-1.31%
Return on Assets-1.05%
Shares Outstanding510.60M
Shares Float325.94M
Beta0.29
Dividend Yield0.22%
Dividend Rate0.04
Payout Ratio285.72%

Dividends

20261×
0.04Jun 1, 2026
20251×
0.17May 27, 2025
20241×
0.25May 23, 2024
20231×
0.58May 29, 2023
20221×
0.16May 30, 2022

Stock Splits

  • Jun 1, 20261.2:1
  • May 29, 20231.8:1